67/m mit einer zervikalen Lymphknotenschwellung

Hauschild A, Dummer R, Schadendorf D et al (2018) Longer follow-up confirms relapse-free survival benefit with Adjuvant Dabrafenib plus Trametinib in patients with Resected BRAFV600-mutant stage III melanoma. J Clin Oncol 22:JCO1801219. https://doi.org/10.1200/JCO.18.01219 ([Epub ahead of print] PubMed PMID: 30343620.238 Studie) Weber J, Mandala M, Del Vecchio M, CheckMate 238 collaborators et al (2017) Adjuvant Nivolumab versus Ipilimumab in Resected stage III or IVmelanoma. N Engl J Med 377(19):1824–1835. https://doi.org/10.1056/NEJMoa1709030 (Epub 2017 Sep 10. PubMed PMID: 28891423) Kähler KC, Hassel JC, Heinzerling L, Loquai C, Mössner R, Ugurel S, Zimmer L, Gutzmer R, “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO) (2016) Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 14(7):662–681. https://doi.org/10.1111/ddg.13047 (PubMed PMID: 27373241) Daud A, Tsai K (2017) Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist 22(7):823–833. https://doi.org/10.1634/theoncologist.2016-0456 (Epub 2017 May 18. Review. PubMed PMID: 28526719; PubMed Central PMCID: PMC5507648)